Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12507005 | 1.00 | POLB (0.47) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL13003862 | 1.00 | POLB (0.47) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL17366260 | 0.94 | CHRM2 (0.45) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL24260483 | 0.85 | POLB (0.53) | POLBL3MBTL1DPP4FAPPREP | |
| SCHEMBL2706064 | 0.83 | POLB (0.50) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL3489993 | 0.82 | POLB (0.48) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL10118444 | 0.82 | POLB (0.48) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL3478725 | 0.82 | POLB (0.48) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL12136792 | 0.82 | POLB (0.70) | POLBL3MBTL1CHRM2CHRM4CHRM5 | |
| SCHEMBL1597060 | 0.82 | POLB (0.48) | POLBL3MBTL1DPP4FAPPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | claimed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | claimed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-9493444-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9493444-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| EP-2807154-B1 | AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2013110433-A1 | AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| WO-2010149684-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-4695574-A | HYPOTENSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | POLB 2084/4885L3MBTL1 3970/4885CHRM2 766/4885 |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | POLB 1500/4885L3MBTL1 4287/4885CHRM2 4129/4885 |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | PCNA, CDKN1A, CCNC | POLB 167/4885L3MBTL1 3453/4885CHRM2 4529/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | POLB 3253/4885L3MBTL1 4767/4885CHRM2 788/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | POLB 3030/4885L3MBTL1 2427/4885CHRM2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.